Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Aaron Tward, MD, PhD

    TitleAssistant Professor
    SchoolUCSF School of Medicine
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      UCLAB.S.Microbiology and Molecular Genetics1999
      UCLAM.A.Microbiology and Molecular Genetics1999
      UCSFPh.D.Biomedical Sciences2005
      Harvard Medical School/Massachusetts Eye and Ear InfirmaryResidencyOtolaryngology - Head and Neck Surgery2012
      Harvard Medical School/Massachusetts Eye and Ear InfirmaryFellowshipNeurotology2014

      Collapse Overview 
      Collapse Overview
      Aaron D. Tward M.D., Ph.D., is a board-certified, fellowship-trained surgeon who specializes in the diagnosis and treatment of disorders of the ear and skull base.

      Dr. Tward has particular clinical interests in cochlear implantation, management of benign and malignant tumors of the skull base including acoustic neuroma (vestibular schwannoma), surgery for chronic otitis media, stapedectomy, superior semi-circular canal dehiscence repair, and endoscopic surgery of the ear and skull base.

      Dr. Tward’s research interests include tumor biology, the genetics and genomics of disorders of the head and neck, and clinical outcomes of surgery of the ear and skull base.

      Education and Training:
      • Undergraduate: University of California, Los Angeles, B.S. - Microbiology and Molecular Genetics
      • Graduate School: University of California, Los Angeles, M.A. - Microbiology and Molecular Genetics, Lab of A. Jake Lusis
      • Graduate School: University of California, San Francisco, Ph.D. - Biomedical Sciences, Lab of J. Michael Bishop
      • Medical School: University of California, San Francisco, M.D.
      • Internship: Brigham and Women’s Hospital, Harvard Medical School - General Surgery

      • Residency: Otolaryngology – Head and Neck Surgery
      Harvard Medical School Residency Program in Otolaryngology
      Massachusetts Eye and Ear Infirmary
      Massachusetts General Hospital
      Brigham and Women’s Hospital
      Beth Israel-Deaconess Medical Center
      Boston Children’s Hospital

      • Clinical Fellowship: Otology, Neurotology, and Skull Base Surgery
      Harvard Medical School
      Massachusetts Eye and Ear Infirmary
      Massachusetts General Hospital
      (Michael J. McKenna and Daniel J. Lee Fellowship directors)

      • Post Doctoral: The Broad Institute of MIT and Harvard
      Lab of Todd R. Golub

      • Diplomate, American Board of Otolaryngology
      • License, Medical Board of California

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, Nomura DK, Goga A. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016 Apr; 22(4):427-32. PMID: 26950360.
        View in: PubMed
      2. Puram SV, Tward AD, Jung DH, Dilger AE, Herrmann BS, Duhaime AC, Barker FG, Lee DJ. Auditory brainstem implantation in a 16-month-old boy with cochlear hypoplasia. Otol Neurotol. 2015 Apr; 36(4):618-24. PMID: 25473959.
        View in: PubMed
      3. Li J, Chanrion M, Sawey E, Wang T, Chow E, Tward A, Su Y, Xue W, Lucito R, Zender L, Lowe SW, Bishop JM, Powers S. Reciprocal interaction of Wnt and RXR-a pathways in hepatocyte development and hepatocellular carcinoma. PLoS One. 2015; 10(3):e0118480. PMID: 25738607; PMCID: PMC4349704.
      4. Mroz EA, Tward AM, Hammon RJ, Ren Y, Rocco JW. Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas. PLoS Med. 2015 Feb; 12(2):e1001786. PMID: 25668320; PMCID: PMC4323109.
      5. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 Jan 29; 517(7536):576-82. PMID: 25631445; PMCID: PMC4311405.
      6. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28; 111(43):15544-9. PMID: 25313082; PMCID: PMC4217452.
      7. Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer. 2013 Aug 15; 119(16):3034-42. PMID: 23696076; PMCID: PMC3735618.
      8. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60. PMID: 21798893; PMCID: PMC3415217.
      9. Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J, Chen X. Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology. 2008 Apr; 47(4):1200-10. PMID: 18214995.
        View in: PubMed
      10. Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A. 2007 Sep 11; 104(37):14771-6. PMID: 17785413; PMCID: PMC1964540.
      11. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med. 2007 Jul; 13(7):820-7. PMID: 17589519.
        View in: PubMed
      12. Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, Gladstone H, Chang HY, Morganroth GS, Oro AE, Brown PO. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A. 2006 Oct 3; 103(40):14842-7. PMID: 17003113; PMCID: PMC1578503.
      13. Bhasin KK, Yu JM, Tward A, Shih D, Campbell DA, Lusis AJ. Trypanosoma congolense: paraoxonase 1 prolongs survival of infected mice. Exp Parasitol. 2006 Nov; 114(3):240-5. PMID: 16682028.
        View in: PubMed
      14. Sheth SS, Bodnar JS, Ghazalpour A, Thipphavong CK, Tsutsumi S, Tward AD, Demant P, Kodama T, Aburatani H, Lusis AJ. Hepatocellular carcinoma in Txnip-deficient mice. Oncogene. 2006 Jun 15; 25(25):3528-36. PMID: 16607285.
        View in: PubMed
      15. Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward AD, Lusis AJ, Costa LG. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology. 2005 Aug; 26(4):651-9. PMID: 16112327.
        View in: PubMed
      16. Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics. 2005 Aug; 15(8):589-98. PMID: 16007003.
        View in: PubMed
      17. Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG. Paraoxonase 1 (PON1) status and risk of insecticide exposure. J Biochem Mol Toxicol. 2005; 19(3):182-3. PMID: 15977192.
        View in: PubMed
      18. Tward AD, Jones KD, Yant S, Kay MA, Wang R, Bishop JM. Genomic progression in mouse models for liver tumors. Cold Spring Harb Symp Quant Biol. 2005; 70:217-24. PMID: 16869757.
        View in: PubMed
      19. Araujo JA, Meng L, Tward AD, Hancock WW, Zhai Y, Lee A, Ishikawa K, Iyer S, Buelow R, Busuttil RW, Shih DM, Lusis AJ, Kupiec-Weglinski JW. Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse. J Immunol. 2003 Aug 1; 171(3):1572-80. PMID: 12874251.
        View in: PubMed
      20. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE. Expression of human paraoxonase (PON1) during development. Pharmacogenetics. 2003 Jun; 13(6):357-64. PMID: 12777966.
        View in: PubMed
      21. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002 Jul 23; 106(4):484-90. PMID: 12135950.
        View in: PubMed
      22. Tward AD, Patterson HA. MSJAMA. From grave robbing to gifting: cadaver supply in the United States. JAMA. 2002 Mar 6; 287(9):1183. PMID: 11879122.
        View in: PubMed
      23. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics. 2000 Dec; 10(9):767-79. PMID: 11191881.
        View in: PubMed
      24. Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab. 1999 Dec; 68(4):419-23. PMID: 10607471.
        View in: PubMed
      Aaron's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP